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ABSTRACT 
 
Background:   
Patient reported outcomes are increasingly incorporated in drug evaluation trials. 
Whether new immunosuppressive drugs result in an improved health-related quality of 
life (HRQoL) and a reduced side effect experiences remains unknown. Moreover, the 
relationship between HRQoL and kidney function has never been investigated in kidney 
transplant recipients.  
Methods:  
Using the BENEFIT and BENEFIT-EXT trials, we investigated the: a) evolution of 
health-related quality of life (HRQoL), assessed by the SF-36 in the first 3 years 
(baseline, 12, 24 and 36 months) after kidney transplantation; b) association between 
kidney function (CKD stage), HRQoL, and patient-reported side-effects (MTSOSD-59R; 
BENEFIT trial only), and c) impact of belatacept and cyclosporine on side effect 
experience and HRQoL.   
Results:  
In the BENEFIT trial, all subjects reported clinically meaningful improvements 
compared to baseline and returned to general population scores, both for physical (PCS) 
and mental composite (MCS) SF-36 scores at 12 to 36 months post-Tx. In the BENEFIT-
EXT trial, this was observed for PCS only. Belatacept-treated patients reported better 
absolute PCS scores compared to cyclosporine-treated patients. Differences were small, 
but statistically significant at all times. Belatacept-treated patients tended to experience 
4 
 
less side effects compared to cyclosporine-treated patients, except for dry skin. 
Worsening kidney function was associated with a significant decrease in HRQoL. 
Conclusion:  
Worsening in kidney function was associated with lower HRQoL. Compared to 
cyclosporine, belatacept was associated with improved HRQoL, suggesting that use of 
non-nephrotoxic immunosuppressants may affect patient’s side effect experience and 
improve their HRQoL. 
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INTRODUCTION 
 
While morbidity and mortality are the ultimate clinical endpoints of interest to transplant 
professionals [1], they do not fully capture the patients’ perspective on how kidney 
transplantantation (KTx) affect their life. Patient reported outcomes (PROs) are being 
adopted as key parameters to fill this gap in clinical outcome evaluation and provide a 
more complete evaluation of medical interventions [2-5], including KTx [6].  
 
Significant improvements in patients’ health-related quality of life (HRQoL) from pre- to 
post-Tx have been reported consistently [1, 7]. Yet, to date, most studies focused on the 
early post-operative period or reported on cross-sectional comparisons of KTx with 
dialysis patients only [8]. Whether HRQoL is restored to a level comparable to that of 
healthy people and whether HRQoL gains are sustainable over the longer-term remains 
poorly understood. To our knowledge, no studies evaluated prospective changes in 
HRQoL over a relatively long post-Tx time, especially comparing distinct types of 
maintenance immunosuppressants.  
 
In patients with chronic kidney disease, reduced HRQoL seems to be a hallmark of 
kidney failure [9, 10]. The presence of various co-morbidities as well as side effects of 
calcineurin inhibitors (CNIs) contribute to a reduced post-Tx HRQoL, such as 
nephrotoxicity, cardiovascular and metabolic problems, as well as  other CNI-related side 
effects, such as hair growth, tremor, or muscle weakness, are not life-threatening but 
occur frequently and are perceived as burdensome by patients [11-13, 16]. Unfortunately, 
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few studies have investigated the relationship between kidney function and HRQoL in 
KTx recipients [14, 15].  
The safety profile of CNIs underscores the need for newer immunosuppressive drugs that 
are able to preserve long-term kidney function, prevent non-renal toxicity and at the same 
time reduce the patients’ perceived immunosuppressants’ side effects. Recently published 
findings from the BENEFIT and BENEFIT-EXT trials show that KTx  patients treated 
with belatacept, a selective costimulation blocker [17], have similar patient and graft 
survival rates, better renal function and improved cardiovascular and metabolic risk 
profiles compared to patients treated with cyclosporine [18-22]. It remains to be 
demonstrated, however, whether patients treated with belatacept also experience more 
beneficial patient reported outcomes, including HRQoL and immunosuppressants side 
effects experience.   
 
This manuscript answers the following research questions: 
1) What is the evolution of HRQoL in the first 3 years after KTx and do patients 
return to a level of HRQoL comparable to the general population? 
2) What is the association between kidney function and PROs (i.e. perceived side-
effects and HRQoL)? 
3) Do patients treated with belatacept experience a more favorable HRQoL and 
fewer side effects compared to patients treated with cyclosporine at 3 years post-
Tx? 
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RESULTS 
 
In the BENEFIT trial (N= 666), 226 patients received LI belatacept and 221 cyclosporine 
treatment .  In the BENEFIT-EXT trial (N= 543) 175 patients were on LI belatacept and 
184 on cyclosporine treatment. Demographic and clinical characteristics are documented 
elsewhere [18-22]. 
SF-36 data at baseline, 12, 24 and 36 months follow-up were available for 91.5%, 89.3%, 
92.6%, and 94.2% of the BENEFIT intention to treat (ITT) population, respectively, 
while 86.9%, 83.8%, 86.7%, and 86.1% of the BENEFIT-EXT ITT population completed 
the SF-36 at the respective time points. The MTSOSD-59R was completed by 72.5%, 
69.1% and 67.3% at 12, 24 and 36 months follow-up, respectively (BENEFIT trial only).   
 
HRQoL 
 
Compared to baseline, all BENEFIT trial subjects reported a clinically-meaningful 
improvement in PCS (range: 4,8-7,0 points) and MCS (2,3-5,9 points) and reached 
general population norms at 12 months post-Tx (figure 1). This improvement was 
sustained up to 36 months post-Tx. In the BENEFIT-EXT trial, improvements were also 
observed, however these changes were smaller in magnitude (0.2-4.1 points for PCS and 
1.5-3.6 for MCS), and the trial population reached general population age-adjusted norms 
for PCS only (Figure 1).  
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Association between HRQoL and kidney function 
Patients with better kidney function had significantly better PCS and MCS than those 
with higher CKD-stages at all time points, except for 12-months BENEFIT and 36-
months BENEFIT-EXT MCS results (see figure 2; month 36 data only).  
 
Patient-reported side effects and their impact on HRQoL 
 
At 12 months post-Tx, patients in BENEFIT experienced on average 20.2 different side 
effects, with a slight increase over time (mean = 20.9 at 24 months and  21.4 at 36 
months). The most frequently experienced side effects (> 60% occurrence) at 36 months 
were wind (73.9%), tiredness (73%), lack of energy (63.9%) and restlessness/nervousness 
(63.2%) (Table 1).  
 
Presence of a greater number of side effects was associated with lower SF-36 PCS and 
MCS, with differences of up to 10 points noted between Q1 and Q4 at all follow-up 
points (Figure 3).  
 
Several side effects had a large and clinically-meaningful impact on PCS and MCS at 36 
months post-Tx, whereas absence of side effects yields HRQoL scores close to those of a 
normal population (Table 1). The largest differences in PCS between patients 
experiencing versus not experiencing a given side effect were noted for breathlessness 
(8.2 points), altered voice (7.8), lack of energy (7.4) muscle weakness (7.3), and joint 
pain (6.1). For MCS, the largest differences were found for depressed mood (14.1 points), 
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anxiety (11.9), restlessness (10.6), mood swings (10), stomach complaints (9.4) and lack 
of energy (9.4).  
 
Impact of belatacept on HRQoL 
Belatacept-treated patients reported better absolute PCS. Absolute PCS differences 
between groups were small (1.7-2.1 points in the BENEFIT trial and 2.3-2.8 in the 
BENEFIT-EXT trail), but statistically significant and clinically meaningful on all 
comparisons (Figure 1). There was no difference between groups for MCS.  
 
Impact of belatacept on patient-reported side-effects 
The number of side effects experienced was significantly lower for the belatacept LI 
group compared to the cyclosporine group at all follow-up times (Figure 4).  
 
A difference in occurrence of at least 5% was reported for 21 side effects, with the 
following 11 side effects occurring less frequently in belatacept-treated patients: oily 
skin, trembling hands, face/back spots, swollen gums, swollen ankles/feet; 
tingling/numbness of fingers or hands; increased hair growth, muscle weakness, lack of 
energy, muscle cramps and shortness of breath. Dry skin was the only side effect that was 
reported more frequently in the belatacept group.  
Patients on belatacept also reported less distress from side effects, yet differences did not 
reach statistical significance (data not shown).  
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DISCUSSION 
 
PROs have started to play a prominent role when evaluating new drug therapies for 
patients with chronic conditions [2-6]. Analyses of the BENEFIT and BENEFIT-EXT 
PRO data revealed that 1) HRQoL improved from pre- to post-Tx, with the beneficial 
effects sustained up to 3 years post-KTx; 2) worsening kidney function is associated with 
a significant decrease in HRQoL; and 3) patients treated with belatacept tended to 
experience less side effects compared to cyclosporine treated patients.  
 
The observed HRQoL improvement from pre- to post-Tx is not surprising: There is an 
almost 100% consensus that HRQoL is better in KTx patients than their dialysis 
counterparts [1, 7, 25, 30]. Yet, given that both groups are typically compared by using 
cross-sectional designs, differences could likely in part be explained by older age and 
higher co-morbidity in dialysis patients [1, 7, 25]. Our study was able to overcome these 
biases by using a prospective repeated-measures design, allowing us to observe long-term 
evolutions in HRQoL within the same cohort and to compare the effect of different 
treatment regimens on HRQoL.  Our pre- to post-Tx improvements in the BENEFIT trial 
were consistent with the 5-7 point differences seen in cross-sectional studies [25]. In 
BENEFIT-EXT, HRQoL improvements were smaller, but also significant and clinically 
relevant (i.e. an incremental 2-3 points change in PCS in addition to improvements seen 
post-Tx in general). To our knowledge, no other immunosuppressive drug testing trial has 
been able to demonstrate this. Improvements in MCS were less prominent, which is 
consistent with previous HRQoL studies that predominantly found physical functioning 
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improvements also [1, 7, 25].  . Interestingly, our post-Tx SF-36 scores are similar to 
those of a healthy population, underscoring that KTx is capable of restoring close to 
normal functioning in most patients [23, 24]. The fact that the majority of patients 
underwent deceased donor KTx and completed the baseline questionnaire post-Tx based 
on their pre-Tx memories might explain why baseline scores were relatively high. 
 
In addition, we found a graded pattern of reduced HRQoL with worsening kidney 
function, illustrating that HRQoL is not a trivial outcome for patients with chronic kidney 
disease. With the exception of one cross-sectional study [15], we are not aware of other 
prospective studies showing that patients in CKD stage 4 and 5 experience a significantly 
reducted HRQoL. Evidence suggests that a PCS below 43 is indicative of perceived 
problems that might impede life functioning [31]. Our observations for patients in stage 4 
and 5 are therefore particularly worrisome and underscore the need for renal sparing 
programs or therapeutic options that are able to reduce nephrotoxicity.  
 
In line with the systematic review of Kugler et al. [16], we found that patients who 
experienced more side effects had a reduced HRQoL. Impact on MCS was particularly 
noted for emotion-related side effects, like depression, anxiety, or restlessness. 
Appropriate interventions might not only reduce these side effects, but segue into a better 
HRQoL, a hypothesis that merits further testing.  
 
Compared to cyclosporine-treated patients, the belatacept group showed significantly 
better PCS in both trials and at all follow-up points, while differences for MCS were not 
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statistically significant. Although both trials consistently show better preserved kidney 
function when treated with belatacept [18-22], we don’t know if better PCS in the 
belatacept groups can be explained by a slower decline in kidney function over time, as 
unfortunately numbers were too small to make meaningful comparisons in HRQoL as a 
function of CKD stage between treatment arms.  
 
Another explanation for the higher HRQoL scores in belatacept-treated patients might be 
found in a more beneficial side effect pattern. Relative to belatacept, patients treated with 
cyclosporine experienced on average 3 more symptoms. Moreover, eleven symptoms 
were significantly more reported, like tremor, gum growth, muscle weakness or excessive 
hair growth. These are consistently ranked among the top 10 most frequently reported 
side effects across studies that include either patients on cyclosporine or tacrolimus [16]. 
Dry skin was the only side effect that belatacept-treated patients reported more 
frequently. Whether these observed side effect profiles would continue to be favorably in 
belatacept- versus tacrolimus-based or other immunosuppressive regimens is unknown.  
In contrast to documentation of adverse events, there is a paucity of studies comparing 
subjective side effect experiences between treatments. A recent study showed that 
switching patients from cyclosporine- to  tacrolimus seem to alleviate occurrence and 
burden of cosmetic effects attributable to cyclosporine such as hypertrichosis and 
gingival hyperplasia. An additional gain of belatacept- versus CNI-based regimens 
remains to be demonstrated [32]. Nevertheless, our findings suggest that evaluation of 
subjective symptom experience might be valuable when professionals select 
immunosuppressive regimens, as patients experience many side effects that are not 
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harmful, but could be distressing and negatively impact their HRQoL. In fact, multiple 
guidelines underscore the relevance of incorporating PROs in selecting treatments or 
when making treatment decisions [2-5]. 
 
Strengths of this paper include the large sample size and the 3 years prospective follow-
up. A first limitation is the reliance on PRO instruments that might not be ideally suited 
for Tx populations. While there are a number of HRQoL instruments that have been used 
in Tx before, Butt and colleagues [33] in their systematic review concluded that none can 
be considered the gold standard and that the SF-36 was by far the most frequently used 
instrument KTx. Similarly, although other self-report instruments exist to measure 
perceived side effects, the MTSOSD equals or exceeds the reliability and validity of other 
instruments. Moreover, the MTSOSD-59R is the only PRO that is validated for use in 
newer immunosuppressive regimens, including belatacept. Secondly, our baseline 
assessment might not reflect actual HRQoL prior to Tx, as deceased donor KTx patients 
completed the questionnaires post-Tx. This might have introduced a recall bias, yet, post-
hoc analyses did not find significant differences in HRQoL scores between those who 
completed the questionnaire 4 weeks prior versus post-Tx. Thirdly, as for all HRQoL 
studies, we only have information about included patients, which might have introduced a 
selection bias and overestimation of post-Tx HRQoL. It is for instance possible that 
patients who discontinued trial participation because of death (N= 3 in the BENEFIT and 
N= 17 in BENEFIT-EXT trial [22, 36]) might have had a poorer HRQOL. Yet, we 
compared our ITT population with those completing the study, and found similar results. 
Similarly, although our HRQoL results at group level are comparable to that of healthy 
14 
 
controls, individual KTx patients might have suboptimal scores that remain invisible by 
the nature of our analyses. Patients who developed post-transplant lymphoproliferative 
disorder (PTLD) for instance, might have experienced a lower quality of life, yet 
numbers were too small (i.e. 11 cases at 3 years follow-up in both trials spread over the 3 
treatment arms) to conduct meaningful statistical comparisons [22; 36]. Likewise, too 
few patients died in both trials, rendering comparisons between survivors and non-
survivors difficult. Fourthly, although more than 85% of patients completed the SF-36 at 
each time point in both trials, only about 70% of the ITT population completed the 
MTSOSD, possibly because no culturally sensitive translations were available for 
specific countries, like e.g. Argentina, Mexico, or Czech Republic. The MTSOSD was 
used in the BENEFIT trial only, hence no information is available on side effect 
experience in the extended criteria donors KTx group. Finally, only comparisons with 
cyclosporine-treated patients were made, making it unclear how patients treated with 
different immunosuppressive regimens relative to belatacept would rate their HRQoL and 
symptom experience over time, representing interesting avenues for further research. 
Studies comparing tacrolimus-based regimens with cyclosporine [34] or tacrolimus-free 
regimens [35] for instance found differences in SF-36 PCS of 1.3 and 3 points in favor of 
tacrolimus, respectively.  
 
Given that lower levels of kidney function (CKD stages 4 and 5) were associated with a 
significant lower HRQoL, and that lower CKD was more common in cyclosporine-
treated patients, our findings suggest that use of non-nephrotoxic immunosuppressant 
agents might have benefits beyond renal function. Appropriate selection of 
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immunosuppressant regimens should consider not only kidney function and survival but 
also the patients’ overall HRQoL.  
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MATERIALS AND METHODS 
 
Design and sample 
 
The methodology of the BENEFIT and BENEFIT-EXT trials is described in detail 
elsewhere [18-22]. In brief, BENEFIT is a 3-year, randomized, active-controlled parallel 
group, multicenter Phase III study conducted at 100 centers worldwide. Eligible adult 
patients having received a living donor or standard criteria deceased KTx were 
randomized 1:1:1 into a more intensive (MI) regimen of belatacept; a less intensive (LI) 
belatacept regimen or cyclosporine for primary maintenance immunosuppression. All 
patients were also treated with basiliximab induction, mycophenolate mofetil and 
corticosteroids.  
BENEFIT-EXT is a 3-year, randomized, multicenter study in adult patients from 79 
centers who received   an extended criteria donor KTx. Patients were randomized into a 
MI or LI belatacept treatment group or cyclosporine. Unless specified otherwise, for most 
analyses, only data for the belatacept LI group will be presented, given that this regimen 
has been approved for use in clinical practice.  
 
Measurements 
 
HRQoL 
The Short Form Health Survey (SF-36 v2) is a widely used generic self-report instrument 
to assess HRQoL that is validated for use in patients with kidney disease, including Tx 
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[23-25]. Patients completed the SF-36 at baseline (within 30 days of Tx), at 12, 24 and 36 
months after KTx. Given that the Tx date in case of deceased donor Tx is not known in 
advance, patients were allowed to complete the baseline questionnaire  post-Tx based on 
their recollection of their HRQoL in the 4 weeks preceding Tx.  
 
The 36 Likert-type questions are classified into 8 subscales, which are summarized into  a 
physical composite score (PCS) and mental composite score (MCS) that are transformed 
to norm-based scores with mean of 50 and standard deviation of 10. For the BENEFIT 
trial, a mean of 50±3 represents a PCS or MCS that is comparable to that of the general 
population. For BENEFIT-EXT, age-adjusted norms were used, given that subjects were 
slightly older,, with a PCS of 47 and a MCS of 52 reflecting a HRQoL comparable to 
age-adjusted general population norms [24]. A 2-point difference in PCS and a 3-point 
difference in MCS are considered as clinically meaningful [23, 24]. 
 
Side effect experience 
The Modified Transplant Symptom Occurrence and Symptom Distress Scale (MTSOSD-
59R), consists of 59 side-effects that patients might experience while taking 
immunosuppressive medications [26]. Side effect occurrence is measured in terms of 
frequency or severity, while symptom distress encompasses mental anguish or suffering 
caused by a specific immunosuppressant side-effect [27].  
 
Patients rate each side-effect on a five-point scale, ranging from 0 (never) to 4 (always 
occurring) for occurrence, and from 0 (not at all distressing) to 4 (extremely distressing) 
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for distress. This scale has been validated to measure side-effects of current and newer 
immunosuppressive drugs, including belatacept [26]. Patients completed the MTSOSD-
59R at 12, 24 and 36 months in the BENEFIT trial only and in countries for which a 
culturally sensitive translation was available.  No baseline measure was completed, given 
that patients were not yet on immunosuppressants treatment pre-Tx  
 
Kidney function 
Calculated GFR (cGFR) in mL/min/1.73 m
2
 was determined at baseline, 12, 24 and 36 
months post-Tx using the Modification of Diet in Renal Disease (MDRD) equation [28] 
and the chronic kidney disease (CKD) stage 1 to 5 classification [29].  
 
Statistical analysis 
 
The analyses focus on the HRQoL, side effect experience, and renal function data only. 
The intention-to-treat (ITT) analyses for the primary and secondary clinical efficacy 
outcomes are reported elsewhere [18-22]. Descriptive statistics are presented as 
appropriate. In the case of missing data, the last observation was carried forward.  
 
Norm-based SF-36 v2 subscale scores, as well as physical composite (PCS) and mental 
composite (MCS) absolute scores and change in scores were compared at 12, 24 and 36 
months post-, using ANOVA.  
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Absolute PCS and MCS were compared between CKD stages 1 to 5 at 12, 24 and 36 
months post-Tx, using ANOVA. Stage 1 and 2, as well as stage 4 and 5 were grouped 
because of the small number of patients especially in the more advanced kidney failure 
stages.  
Differences between belatacept LI and cyclosporine-treated groups norm-based SF-36 v2, 
subscales, PCS and MCS absolute scores relative to pre-Tx were compared at baseline, 
12, 24 and 36 months, using ANOVA.  
Symptom frequency between both groups was compared by independent student’s t-
testing. Scores per symptom were dichotomized first as “symptom not experienced” 
(MTOSD-59R score = 0) versus “symptom occurring” (MTOSOSD-59R scores 1, 2, 3 or 
4) and summed. For distress, mean scores were calculated. Total number of side effects 
experienced were also divided into quartiles (Q1-Q4), allowing comparison of PCS and 
MCS between quartiles at the different time points, using ANOVA.  
Data were analyzed using SAS 9.2. Statistical significance was set at p< 0.05. 
 
 
20 
 
REFERENCES 
 
1. Tonelli M, Wiebe N, Knoll G, et al. Systematic review: kidney transplantation 
compared with dialysis in clinically relevant outcomes. Am J Transplant 2011; 
11: 2093. 
2. Acquadro C, Berzon R, Dubois D, et al. Incorporating the patient’s perspective 
into drug development and communication: an ad hoc task force report of the 
patient-reported outcomes (PRO) harmonization group meeting at the Food and 
Drug Administration, February 16, 2001. Value Health 2003; 6(5): 522. 
3. Patrick DL, Burke LB, Powers JH, et al. Patient-report outcomes to support 
medical product labeling claims: FDA perspective. Value Health 2007; 10(Suppl 
2): S125. 
4. Food and Drug Administration Guidance for industry: patient-report outcome 
measures: use in medical product development to support labeling claims. 
Published online Dec, 2009.  
(http://www.fda.gov/drugs/guidanceComplianceRegulatoryInformation/Guidance/
default.htm  accessed Oct 14, 2011). 
5. European Medicines Agency reflection paper on the regulatory guidance for the 
use of health-related quality of life measures (HRQL) in the evaluation of medical 
products. Jan 2006. 
http://www.emea.europa.eu/docs/en_GB/document_library/Scientific_guideline/2
009/09/WC500003481.pdf (accessed Oct 14, 2011). 
21 
 
6. Cleemput I, Dobbels F. Measuring patient reported outcomes in solid organ 
transplant recipients: an overview of instruments developed to date. 
Pharmacoeconomics 2007; 25(4): 269. 
7. Cameron JI, Whiteside C, Katz J, et al. Differences in quality of life across renal 
replacement therapies: a meta-analytic comparison. Am J Kidney Dis 2000; 
35(4): 629. 
8. Griva K, Stygall J, Ng JH, et al. Prospective changes in health-related quality of 
life and emotional outcomes in kidney transplantation over 6 years. J Transplant 
2011; article ID 671571. 
9. Gorodetskaya I, et al. Health-related quality of life and estimates of utility in 
chronic kidney disease. Kidney Int 2005; 68(6): 2801. 
10. Rossert J, et al. Effect of early correction of anemia on the progression of CKD. J 
Kidney Dis 2006; 47(5): 738. 
11. Fiebiger W, Mitterbauer C, Oberbauer R. Health-related quality of life outcomes 
after kidney transplantation. Health Qual Outcomes 2004; 2:2. 
12. Fellstrom B, Jardine AG, Soveri I, et al. Renal dysfunction is a strong and 
independent risk factor for mortality and cardiovascular complications in renal 
transplantation. Am J Transplant 2005; 5: 1986. 
13. Dobbels F, De Bleser L, De Geest S, et al. Quality of life after kidney 
transplantation: the bright side of life? Adv Chron Kidney Dis 2007; 14(4): 370. 
14. Bohlke M, Marini SS, Rocha M, et al. Factors associated with health-related 
quality of life after successful kidney transplantation: a population-based study. 
Qual Life Res 2009; 18: 1185. 
22 
 
15. Neri L, Dukes J, Brenman DC, et al. Impaired renal function is associated with 
worse self-reported outcomes after kidney transplantation. Qual Life Res 2011; 
20(10):1689.  
16. Kugler C, Geyer S, Gottlieb J, et al. Symptom experience after solid organ 
transplantation. J Psychosom Res 2009; 66(2): 101. 
17. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y 
(belatacept), a high-affinity variant of CLTLA4-Ig with potent 
immunosuppressive properties. Am J Transplant 2005; 5: 443. 
18. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of 
belatacept-based immunosuppression regimens versus cyclosporine in renal 
transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535. 
19. Durbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus 
cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT 
study). Am J Transplant 2010; 10: 547. 
20. Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are 
associated with improved cardiovascular and metabolic risk factors compared 
with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT 
Studies). Transplantation 2011; 91: 976. 
21. Larsen CP, Grinyo J, Medina-Pestana J, et al. Belatacept-based regimens versus a 
cyclosporine A-based regimen in kidney transplant recipients: 2-year results from 
the BENEFIT and BENEFIT-EXT studies. Transplantation 2010; 90: 1528. 
23 
 
22. Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a 
randomized, active-controlled, parallel group study in adult kidney transplant 
recipients. Am J Transplant 2012; 12(1): 210. 
23. Ware J.E., Kosinski M., Dewey J.E. How to Score Version Two of the SF-36 
Health Survey. Lincoln, RI: QualityMetric, Incorporated, 2000.  
24. Ware JE Jr, Bjorner JB, Kosinski M. SF-36 health survey: manual and 
interpretation guide, 2nd edn. Lincoln, RI: QualityMetric 2007. 
25. Liem YS, Bosch JL, Arends LR, et al. Quality of life assessed with the medical 
outcomes study short form 36-item health survey of patients on renal replacement 
therapy: A systematic review and meta-analysis. Value Health 2007; 10: 5:390. 
26. Dobbels F, Moons P, Araham I, et al. Measuring symptom experience of side-
effects of immunosuppressive drugs: the Modified Transplant Symptom 
Occurrence and Distress Scale. Transplant Int 2008; 21 (8): 764. 
27. Rhodes VA, Watson PM. Symptom distress, the concept: past and present. Semin 
Oncol 1987; 3: 242. 
28. Levey AS, Bosch JP, Lewis JB, et al. Modification of Diet in Renal Disease Study 
Group. A more accurate method to estimate glomerular filtration rate from serum 
creatinine: A new prediction equation. Ann Intern Med 1999; 130: 461. 
29. Levey AS, Eckhardt K, Tsukamoto Y, et al. Definition and classification of 
chronic kidney disease: A position statement fro Kidney Disease: Improving 
global outcomes (KDIGO). Kidney Int 2005; 67: 2089. 
24 
 
30. Landreneau K, Lee K, Landreneau MD. Quality of life in patients undergoing 
hemodialysis and renal transplantation – A meta-analytic review. Nephrol Nurs J 
2010; 37(1): 37. 
31. Blanchard CM, Cote I, Feeny D. Comparing short form and RAND physical and 
mental health summary scores: results from total hip arthroplasty and high-risk 
primary care patients. Int J Tech Assess Health Care 2004; 20: 230. 
32. Rostaing L, Sa’nchez-Fructuoso A, Franco A, et al. Conversion to tacrolimus 
once-daily from ciclosporin in stable kidney transplant recipients: a multicenter 
study. Transplant Int 2012; 25: 391. 
33. Butt Z, Yount SE, Caicedo JC, et al. Quality of life assessment in renal transplant: 
review and future directions. Clin Transplant 2008; 22: 292.  
34. Reimer J, Franke GH, Philipp T, et al. Quality of life in kidney recipients: 
comparison of tacrolimus and cyclosporine-microemulsion. Clin Transplant 2005;  
16(1): 48. 
35. Bohlke M, Rocha M, Gomes RH, et al. Tacrolimus and quality of life after 
kidney transplantation – a multicenter study. Clin Transplant 2006; 20(4): 504. 
36. Medina Pestana JO; Grinyo JM, Vanrenterghem Y, et al. Three-year outcomes 
from BENEFIT-EXT: A phase III study of belatacept versus cyclosporine in 
recipients of extended criteria donor kidneys. Am J Transplant 2012; 12: 630. 
25 
 
Table 1: prevalence of experienced side effects and their impact on Physical 
Composite score (PCS) and Mental Composite Score (MCS) at 36 months post-
transplant in BENEFIT trial 
  Physical composite score 
(PCS) 
Mental Composite Score 
(MCS) 
Side effect as 
assessed by 
MTSOSD-59R 
% of 
patients 
in which 
side 
effect is 
occurring 
PCS if 
Side 
effect 
absent 
PCS if 
Side 
effect 
present 
Absolute 
difference 
in PCS 
MCS if 
Side 
effect 
absent 
MCS if 
Side 
effect 
present 
Absolute 
difference 
In MCS 
Warts on hands or feet 7,4% 48,7 47,8 0,9 48,3 45,4 2,9 
Warts around genitals 7,5% 48,7 47,5 1,2 48,3 44,7 3,6 
Swollen glands in 
neck, armpit or groin 
7,9% 48,7 47,9 0,8 48,5 43,1 5,4 
Altered voice 11,1% 49,5 41,7 7,8 48,8 41,8 7,0 
Fat deposits on neck 
and back 
12,3% 48,8 47,7 1,1 48,9 42,3 6,6 
Swollen gums 15,3% 48,7 48,4 0,3 48,7 44,4 4,3 
Abnormal skin color 15,4% 49,4 44,6 4,8 49,3 41,1 8,2 
Larger breasts 16,7% 49,0 46,7 2,3 48,7 45,1 3,6 
Changed taste 17,9% 49,6 44,3 5,3 49,4 42,2 7,2 
Skin rash 20,7% 49,0 47,0 2,0 48,8 45,2 3,6 
Low appetite 21,9% 49,8 45,7 4,1 49,6 44,0 3,6 
Redness of face and 
neck 
22,1% 49,2 46,7 2,5 48,9 45,3 3,6 
Changed facial 
features 
22,1% 49,4 46,0 3,4 49,8 42,0 7,8 
Chest pain 22,3% 49,6 45,2 4,4 49,8 42,3 7,5 
Brittle nails 24,2% 49,3 46,4 2,9 48,5 46,8 1,7 
Puffy face (moon 
face) 
24,6% 49,5 45,9 3,6 49,5 43,7 5,8 
Sores on lips or in 
mouth 
25,6% 49,0 47,7 1,3 49,2 44,9 4,3 
Feeling of warmth in 
hands or feet 
25,8% 49,4 46,4 3,0 49,3 44,7 4,6 
Hearing loss 26,7% 49,8 45,4 4,4 49,2 45,1 4,1 
Stomach complaints 
or nausea 
28,1% 50,1 44,7 5,4 50,7 41,3 9,4 
Palpitations 30,2% 49,9 45,7 4,2 49,8 44,2 5,6 
Increased hair growth 30,9% 48,8 48,3 0,5 48,7 46,8 1,9 
Nightmares 31,2% 50,0 45,6 4,4 50,8 42,0 8,8 
Brittle skin 31,4% 49,8 46,0 3,8 49,7 44,6 5,1 
Oily skin 31,9% 48,7 48,5 0,2 48,5 47,2 1,3 
Spots on face and/or 
back 
32,6% 48,5 48,9 -0,4 49,2 45,8 3,4 
Constipation 35,3% 49,8 46,3 3,5 49,7 45,0 4,7 
Menstrual (female) / 
erectile problems 
(men) 
36,0% 49,6 46,8 2,8 49,4 45,7 3,7 
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Breathlessness 36,0% 51,2 44,0 8,2 50,3 44,1 6,2 
Swollen ankles 37,2% 50,3 45,8 4,5 49,2 46,3 2,9 
Muscle cramps 37,5% 50,3 45,8 4,5 50,0 44,8 5,2 
Tingling or numbness 
in hands or feet 
38,6% 50,2 46,1 4,1 49,8 45,3 4,5 
Itching 39,5% 49,8 46,8 3,0 49,5 45,9 -0,4 
Hair loss 39,5% 49,0 48,1 0,9 49,1 46,5 2,6 
Diarrhea 40,0% 49,6 47,1 2,5 49,8 45,4 4,4 
Dizziness 40,2% 50,7 45,5 5,2 50,9 44,0 6,9 
Trembling hands 40,9% 50,4 46,1 4,3 50,3 44,8 5,9 
Dry skin 43,0% 49,6 47,3 2,3 49,2 46,5 2,7 
Blurred vision 43,3% 50,4 46,3 4,1 50,4 45,1 5,3 
Easy bruising 43,7% 50,6 46,1 4,5 50,0 45,6 4,4 
Reduced interest in 
sex 
44,9% 50,8 45,9 4,9 51,3 44,1 7,2 
Increased urge to 
urinate 
45,4% 50,1 46,9 3,2 49,9 45,9 4,0 
Increased sensitivity 
to light 
45,6% 50,1 46,8 3,3 50,3 45,5 4,8 
Depressed mood 46,0% 50,9 45,9 5,0 54,5 40,4 14,1 
Muscle weakness 47,0% 52,1 44,8 7,3 52,2 43,5 8,7 
Increased sweating 47,2% 49,2 47,9 1,3 49,9 46,1 3,8 
Join pain 48,2% 51,6 45,5 6,1 50,1 45,9 4,2 
Anxiety 48,9% 50,7 46,4 4,3 53,9 42,0 11,9 
Concentration or 
memory difficulties 
49,5% 50,7 46,5 4,2 51,2 44,9 6,3 
Headaches 50,4% 49,9 47,4 2,5 51,0 45,2 5,8 
Back pain 52,8% 51,4 46,2 5,2 51,9 44,7 7,2 
Increased thirst 53,5% 50,2 47,3 2,9 49,7 46,7 3,0 
Sleep problems 54,7% 50,9 46,8 4,1 51,5 45,3 6,2 
Mood swings 56,0% 51,1 46,7 5,4 53,7 43,7 10,0 
Increased appetite 58,4% 49,4 48,1 1,3 49,5 47,1 2,4 
Restlessness / 
nervousness 
63,2% 51,0 47,2 3,8 54,8 44,2 10,6 
Lack of energy 63,9% 53,4 46,0 7,4 54,1 44,7 9,4 
Tiredness 73,0% 53,0 47,1 5,9 53,3 46,0 7,3 
Increased wind 73,9% 50,0 48,1 1,9 49,9 47,5 2,4 
MTSOSD-59R: Modified Transplant Symptom Occurrence and Symptom Distress Scale (59 items revised version) 
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OVERVIEW OF FIGURES 
 
Figure 1:  SF-36 Physical Composite Score (PCS) and Mental Composite Score 
(MCS) for belatacept LI and cyclosporine groups 
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Figure 2:  Association between Health-related quality of life (HRQoL) and Chronic 
Kidney Disease (CKD) stage at 36 months post-Tx 
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Figure 3:  Association between Health-related quality of life (HRQoL) and 
occurrence of side effects 
 
 
 
30 
 
 
Figure 4:  Comparison of total number of side effects between belatacept LI and  
  cyclosporine groups 
 
 
